Category Archives: Regenerative Medicine

The organ of Corti, the hearing organ of the inner ear, contains rows of sensory hearing cells (green) surrounded by supporting cells (blue). Credit: Image by Yassan Abdolazimi/Segil Lab/USC Stem Cell

Scientists from the USC Stem Cell laboratory of Neil Segil have identified a natural barrier to the regeneration of the inner ears sensory cells, which are lost in hearing and balance disorders. Overcoming this barrier may be a first step in returning inner ear cells to a newborn-like state thats primed for regeneration, as described in a new study published inDevelopmental Cell.

Permanent hearing loss affects more than 60 percent of the population that reaches retirement age, said Segil, who is a Professor in the Department of Stem Cell Biology and Regenerative Medicine, and the USC Tina and Rick Caruso Department of Otolaryngology Head and Neck Surgery. Our study suggests new gene engineering approaches that could be used to channel some of the same regenerative capability present in embryonic inner ear cells.

In the inner ear, the hearing organ, which is the cochlea, contains two major types of sensory cells: hair cells that have hair-like cellular projections that receive sound vibrations; and so-called supporting cells that play important structural and functional roles.

When the delicate hair cells incur damage from loud noises, certain prescription drugs, or other harmful agents, the resulting hearing loss is permanent in older mammals. However, for the first few days of life, lab mice retain an ability for supporting cells to transform into hair cells through a process known as transdifferentiation, allowing recovery from hearing loss. By one week of age, mice lose this regenerative capacityalso lost in humans, probably before birth.

Based on these observations, postdoctoral scholar Litao Tao, PhD, graduate student Haoze (Vincent) Yu, and their colleagues took a closer look at neonatal changes that cause supporting cells to lose their potential for transdifferentiation.

In supporting cells, the hundreds of genes that instruct transdifferentiation into hair cells are normally turned off. To turn genes on and off, the body relies on activating and repressive molecules that decorate the proteins known as histones.In response to these decorations known as epigenetic modifications, the histone proteins wrap the DNA into each cell nucleus, controlling which genes are turned on by being loosely wrapped and accessible, and which are turned off by being tightly wrapped and inaccessible. In this way, epigenetic modifications regulate gene activity and control the emergent properties of the genome.

In the supporting cells of the newborn mouse cochlea, the scientists found that hair cell genes were suppressed by both the lack of an activating molecule, H3K27ac, and the presence of the repressive molecule, H3K27me3.However, at the same time, in the newborn mouse supporting cells, the hair cell genes were kept primed to activate by the presence of yet a different histone decoration, H3K4me1.During transdifferentiation of a supporting cell to a hair cell, the presence of H3K4me1 is crucial to activate the correct genes for hair cell development.

Unfortunately with age, the supporting cells of the cochlea gradually lost H3K4me1, causing them to exit the primed state. However, if the scientists added a drug to prevent the loss of H3K4me1, the supporting cells remained temporarily primed for transdifferentiation. Likewise, supporting cells from the vestibular system, which naturally maintained H3K4me1, were still primed for transdifferentiation into adulthood.

Our study raises the possibility of using therapeutic drugs, gene editing, or other strategies to make epigenetic modifications that tap into the latent regenerative capacity of inner ear cells as a way to restore hearing, said Segil. Similar epigenetic modifications may also prove useful in other non-regenerating tissues, such as the retina, kidney, lung, and heart.

Reference: Enhancer decommissioning imposes an epigenetic barrier to sensory hair cell regeneration by Litao Tao, Haoze V. Yu, Juan Llamas, Talon Trecek, Xizi Wang, Zlatka Stojanova, Andrew K. Groves and Neil Segil, 30 July 2021, Developmental Cell.DOI: 10.1016/j.devcel.2021.07.003

Additional co-authors of the study include Juan Llamas, Talon Trecek, Xizi Wang, andZlatka Stojanovain the Segil Lab at USC, and Andrew K. Groves at Baylor College of Medicine.

Sixty percent of this project was supported by federal funding from the National Institute on Deafness and Other Communication Disorders (R01DC015829, R01DC014832, T32DC009975, F31DC017376). Additional funding came from the Hearing Restoration Project at the Hearing Health Foundation.

See the original post here:
Stem Cell Scientists Explore the Latent Regenerative Potential of the Inner Ear - SciTechDaily

STONY BROOK AND ROCKVILLE CENTRE, NY August 4, 2021 Stony Brook Medicine (SBM) and Catholic Health (CH) have signed a letter of intent to explore a collaboration that would expand leading-edge academic medicine and advanced clinical care and deliver greater health care options to Long Islanders.

This potential collaboration will improve patient care, offer new services and enhance medical education for both systems, said Catholic Health President & Chief Executive Officer Patrick M. OShaughnessy, DO, MBA. There will be additional options for physicians and high quality, high value services for all Long Islanders.

This relationship will include the development of an integrated strategic and clinical plan to grow and align trauma services, pediatric capabilities, clinical service lines and training opportunities for medical residents in the health care systems and for students in Stony Brook Universitys Renaissance School of Medicine, added Margaret M. McGovern, MD, PhD, Dean for Clinical Affairs, Renaissance School of Medicine at Stony Brook University and Vice President, Health System Clinical Programs and Strategy, Stony Brook Medicine. By expanding training options, we will enable a more robust learning experience and lead to a talented, well prepared and persistent stream of incoming practitioners serving our Long Island communities.

The proposed relationship affords the two health systems a unique opportunity to work together on key initiatives while remaining separate and independent in all other respects. Other projects may include population health initiatives and further options for care coordination.

This collaboration is a natural outcome of the synergies of both organizations longstanding reputation for excellence in the community, state-of-the-art facilities and services, leading-edge technology and increasing focus on academic excellence and expanding clinical research opportunities.

About Stony Brook Medicine:

Stony Brook Medicine encompasses all of Stony Brook Universitys health-related initiatives: education, research and patient care. It includes five Health Sciences schools Dental Medicine, Health Technology and Management, Renaissance School of Medicine, Nursing and Social Welfare as well as Stony Brook University Hospital, Stony Brook Southampton Hospital, Stony Brook Eastern Long Island Hospital, Stony Brook Childrens Hospital and more than 200 community-based healthcare settings throughout Suffolk County. To learn more, visitstonybrookmedicine.edu.

About Stony Brook University Hospital:

Stony Brook University Hospital (SBUH) is Long Islands premier academic medical center. With 624 beds, SBUH serves as the regions only tertiary care center and Regional Trauma Center, and is home to the Stony Brook University Heart Institute, Stony Brook University Cancer Center, Stony Brook Childrens Hospital and Stony Brook University Neurosciences Institute. SBUH also encompasses Suffolk Countys only Level 4 Regional Perinatal Center, state-designated AIDS Center, state-designated Comprehensive Psychiatric Emergency Program, state-designated Burn Center, the Christopher Pendergast ALS Center of Excellence, and Kidney Transplant Center. It is home of the nations first Pediatric Multiple Sclerosis Center. To learn more, visitstonybrookmedicine.edu/sbuh.

About the Renaissance School of Medicine at Stony Brook University:

Established in 1971, Renaissance School of Medicine at Stony Brook University includes 25 academic departments. The three missions of the School are to advance the understanding of the origins of human health and disease; train the next generation of committed, curious and highly capable physicians; and deliver world-class compassionate healthcare. As a member of the Association of American Medical Colleges (AAMC) and a Liaison Committee on Medical Education (LCME) accredited medical school, Stony Brook is one of the foremost institutes of higher medical education in the country. Each year the School trains over 600 medical students and more than 750 medical residents and fellows. Faculty research includes National Institutes of Health-sponsored programs in neurological diseases, cancer, cardiovascular disorders, biomedical imaging, regenerative medicine, infectious diseases, and many other topics. Physicians on the School of Medicine faculty deliver world-class medical care through more than 31,000 inpatient, 104,000 emergency room and 1 million outpatient visits annually at Stony Brook University Hospital and affiliated clinical programs, making its clinical services one of the largest and highest quality medical schools on Long Island, New York. To learn more, visitrenaissance.stonybrookmedicine.edu.

About Catholic Health:

With approximately 17,000 employees, Catholic Health is an integrated system serving Long Islands many communities. With more than 4,600 medical staff and 4,000 nurses, the health system has an extensive network of ambulatory care locations and physician practices, 6 hospitals and a continuing care division encompassing skilled nursing and rehabilitation, home nursing and hospice care. Under the sponsorship of the Diocese of Rockville Centre, Catholic Health provides services that extend from the beginning of life to helping people live their final years in comfort, grace and dignity.

Combined, St. Francis Hospital & Heart Center, Good Samaritan Hospital, Mercy Hospital, St. Charles Hospital, St. Catherine of Siena Hospital and St. Joseph Hospital have more than 1,900 certified hospital beds, and the health system also has 685 nursing home beds. Catholic Health Physician Partners has more than 450 employed providers in approximately 90 locations across Nassau and Suffolk counties.

Catholic Health excels in cardiac services, with St. Francis Hospital & Heart Center being nationally ranked byU.S. News & World Reportfor Cardiology & Heart Surgery (20202021)more times than any other hospital in the region in this specialty. St. Francis Heart Center services are available in both Nassau and Suffolk. Additionally, the health care system is widely recognized for oncology services, and its cancer institute has four locations across the Island.

Good Samaritan is one of just seven hospitals nationwide to receive the Outstanding Achievement Award from the American College of Surgeons (ACS) Commission on Cancer for 18 consecutive years. It is also the only ACS-Verified Level 2 Trauma Center for both adults and pediatrics on the south shore of Long Island.

All six Catholic Health hospitals are designated stroke centers and have received the Get With The Guidelines Stroke Gold Plus Quality Achievement Award from the American Stroke Association. Also, they have each earned The Joint Commissions Gold Seal of Approval and are fully accredited.To learn more, please seeAwards and Recognition | CHSLI.

For a quarter of a century, Catholic Healths Good Samaritan Hospital (GSH) has attracted numerous medical graduates to its residency programs because of its stellar reputation across a number of medical specialties, many involving complex care and treatment. These programs include emergency medicine, family medicine, pediatrics, podiatric surgery and OB/GYN, as well as fellowship training programs in pediatric emergency medicine and minimally invasive gynecologic surgery. As part of Catholic Health, a patient-focused health care system, students/residents who complete their training at GSH have a number of worthwhile career paths to consider across our six hospitals and a large number of employed practices.

Read the original:
Stony Brook Medicine and Catholic Health Discuss Collaboration; Expanding Health Care Options for Long Islanders | | SBU News - Stony Brook News

The next major development in Israels life science industry is coming from a microscopic source. Biotech based on the tiny building blocks of life is a sector positioned to unlock new discoveries and drive economic growth in the future.

Although the Start-Up Nation is a well-deserved nickname, I believe Biotech Nation will soon be a better fit.

Biotechnology accounts for more than one-quarter of the countrys life science scene. There are currently 468 active biotech firms, employing thousands of high-skilled workers.

cnxps.cmd.push(function () { cnxps({ playerId: '36af7c51-0caf-4741-9824-2c941fc6c17b' }).render('4c4d856e0e6f4e3d808bbc1715e132f6'); });

And the industry is evolving in new directions.

We are amid a bio-convergence revolution. This means that biology research increasingly leverages multidisciplinary talent, such as computer engineers, big data scientists, artificial intelligence and advanced manufacturing.

The results are broader capabilities, bolder aspirations and bigger breakthroughs. IATI views bio-convergence as the next major economic growth engine for Israel.

The government is also betting on bio-convergence.

Since the Israel Innovation Authority launched CRISPR-IL, a consortium that combines artificial intelligence and CRISPR capabilities to develop genome editing tools, our leading scientists and biotech companies are joining forces to find new treatments and cures.

I am proud Pluristem is teaming up with this initiative. Partnerships like CRISPR-IL are setting an exemplary model that will lead to many more industry disruptions.

It should come as no surprise that when compared to the rest of the world, Israel spends the highest percentage of GDP on research and development. We already have 300 research groups and 30 academic centers working on bio-convergence R&D.

I have observed that in the wake of the COVID-19 pandemic, interest in regenerative medicine research skyrocketed. At Pluristem, we are developing cell-based therapeutics derived from donated placentas to potentially treat hematological deficiencies, radiation exposure, and muscle injuries related to hip fracture surgery.

Now, there are more 1,000 regenerative medicine trials active around the world. The Alliance for Regenerative Medicine reports that about 85% are in Phase I or II studies. Pluristem has one of the few in Phase III: our PLX-PAD product candidate to support muscle regeneration following hip fracture surgery may be the first approved treatment of its kind.

Early on, we knew that it would also be critical to have our own proprietary cell manufacturing technology that could be scalable from research to commercial use. So, we developed a three-dimensional micro-environment mimicking the conditions in the human body, which allows us to expand our placenta cells and transform them to cell therapy products. This result is only made possible by a cross section of talent from clinical and technology backgrounds, demonstrating the power of bio-convergence.

Its not a moment too soon. Most countries face demographic headwinds, such as aging and declining populations. Many developed nations are already experiencing these trends coupled with skyrocketing health care costs. The world will see a surge in demand for new treatments and ways to control healthcare spending.

The Israeli approach, leveraging out-of-the-box thinking, a spirit of innovation, and a long track record of breakthrough treatments, can convert these challenges into opportunities.

Technology is a force that brings people together, across professional fields, cultures, and borders. When advanced technology is paired with cutting edge medical research, we have the power to craft the future we want.

As IATI reports, our biotech sector is full of boundless opportunities. Israel is one of the greatest places in the world for biotech companies to thrive.

The writer is CEO and president of Pluristem. He is also a board member and former co-chairman of Israel Advanced Technology Industries, and served as CFO of Elbit Vision Systems.

The rest is here:
Israel: The 'Start-Up Nation' is now the 'Biotech Nation' - opinion - The Jerusalem Post

CHICAGO (CBS) Its a treatment that could help keep COVID-19 patients off ventilators, and researchers at the University of Illinois Chicago are on the forefront of developing it.

CBS 2 Investigator Megan Hickey sat down exclusively with the scientist who made the discovery and is getting a $6 million grant to make it happen.

Its called VT-109 and it was created to prevent lung damage that plagues COVID 19 patients. Not only could it help keep patients from having to use a ventilator, it could help save lives.

Yulia Komarova has been working on this drug for years well before COVID-19 hit.

You have to be very persistent when you work in academia, especially on the drug development programs, Komarova said.

FULL INTERVIEW: Yulia Komarova Of UIC On A Treatment That Could Keep COVID Patients Off Ventilators

The UIC associate professor in the Department of Pharmacology and Regenerative Medicine said its been shown to prevent lung damage by tightening the barrier between the bloodstream and the lungs.

Help them to restore the lung function and the function of the other organs because everything depends on the lung function, Komarova said.

Not just prevent lung damage, but this drug has shown to restore lung function. Survival in the animals treated with VT-109, that otherwise would have likely died, was 80%.

Within the first few months of the pandemic, it became clear to Komarova and her team that the implications for human COVID-19 patients were worth investigating.

They applied for the grant in June 2020 and were just awarded $6 million from the Department of Defense.

The studies are very expensive because It involves good laboratory practice, Komarova said.

Theyre still at the beginning of a long road. But the grant is an honor for Komarova, who came to Chicago from Russia two decades ago to do this important work.

Its also an honor for her team at UIC, which is hoping theyll be able to make a significant dent in COVID-19 fatalities in the years to come.

We expect that we can save the majority of the patients, Komarova said.

Komarova hopes to apply for the FDAS new investigational drug program by July 2024, although shes hopeful it could happen before then.

Go here to see the original:
UIC Researchers Receive $6M For COVID-19 Treatment To Help Keep People Off Ventilators; Scientist Explains How It Works In Exclusive CBS 2 Interview -...

Exhibiting a Consolidated Market Attribute, Top Five Players Accounted for more than 20% Revenue Share in Global Bioactive Materials Market

Rising cases of age borne tissue damage especially in geriatric population and increasing use of bioactive materials to create regenerative medicine will drive the bioactive material market. Fact.MR offers incisive survey covering insights into key segments within the market in terms of material, type, and application.

NEW YORK, Aug. 4, 2021 /PRNewswire/ --Fact.MR A Market Research and Competitive Intelligence Provider: The bioactive materials market revenue totaled $2.0 Billion in 2020, according to a Fact.MR study. The overall bioactive materials sales is expected to reach US$ 6.2 billion by the end of 2031, growing at a CAGR of 11.3% for 2020- 31.

The demand for bioactive composite materialswill continue accelerating, rendering the market highly competitive. Amidst this, Fact.MR estimates the top 5 players to account for more than 22% of bioactive materials market in 2021.

Bioactive materials are proven to be effective when used for in-situ drug delivery applications. Researchers have found that bioceramicsare excellent carriers of antibiotic, anti-osteoporotic, and anticancer compounds due to its high carrier suitability.

These materials also have showcased positive results in reducing peri-implant traumas and enabling tissue regrowth. These factors are expected to spur the demand for bioactive materials in bioengineering application.

Besides this, application in regenerate dental hard tissuesand manufacturing dental consumables will emerge as a chief growth driver. The World Health Organization (WHO)reports that around 3.5 billion suffer from oral problem across the world.

Increasing cases of periodontal diseases, problems associated with gingival tissues and dental impairments are fueling the demand for dental consumables which in turn is driving the bioactive materials market demand.

Growing prevalence of musculoskeletal disorders such as osteoporosis, osteoarthritis, and rheumatoid arthritis is fueling the demand for orthopedic implants. Bioactive materials are used in manufacturing orthopedic implants owing to their light weight, high flexibility and biochemical inert properties.

Increasing focus on research activities to identify suitable bioactive materials for implants to reduce trauma amongst patients will pave way for a positive demand outlook.

"Bioactive materials application is expected to soar in the food packaging industry. As a result of commercialization, the demand for packaging material that keeps perishable food items fresh for long period of time is at all-time high. Increasing use of bioactive materials for producing eco-friendly coating for paper packaging will therefore boost the market," said a lead analyst at Fact.MR.

For More Information On How To Improve Your Agricultural Films Market Footprint, Request A Sample Here

https://www.factmr.com/connectus/sample?flag=S&rep_id=6537

Key Takeaways

Prominent Drivers

Key Restraints

Ask Your Agricultural Films Market Related Questions & Get Customized Reports https://www.factmr.com/connectus/sample?flag=RC&rep_id=6537

Competitive Landscape

Rise in geriatric population and increasing demand for tissue repair is motivating market players to develop regenerative medicines through collaboration and partnership with other market players. Growing popularity of tissue engineering has created ideal condition for biomedical suppliers to enter new markets.

For instance, Arthrex signed a distribution agreement with Celularity in July 2021. Under this agreement, Arthrex will gain distribution and commercialization rights to Celularity's orthopedic biomaterial products.

Lineage Cell Therapeutics Inc. under pre-negotiated terms issued a royalty-bearing license to Amasa Therapeutics Inc. in June 2021, to use HyStem technology of Lineage Cell Therapeutics for developing treatment for solid tumors and marketing of treatment therapies.

More Valuable Insights on Bioactive Materials Market

Fact.MR, in its new report, offers an unbiased analysis of the global bioactive materials market, analyzing forecast statistics through 2021 and beyond. The study reveals growth projections on in bioactive materials market on the basis of various segments. These include:

Key Questions Covered in the Report

Explore Fact.MR's Coverage on the Chemical & Materials Domain

Bioceramics Market- Dentists are utilising cutting-edge implant options to avoid tooth loss in individuals suffering from such illnesses. As a result, the popularity of bioceramics is fast increasing. Bioceramic implants are the favoured implant choice among dental practitioners since they are non-toxic and bioinert. Carbon bioceramics sales are expected to increase at a potential CAGR through 2031, owing to its high density and increased fibre strength.

Drug Delivery Systems Market- Polymeric drug delivery is particularly beneficial in the treatment of chronic illnesses such as cancer, particularly solid tumors. It also has a reduced level of toxicity. During the projection period, the polymeric drug delivery segment will account for more than one-third of the worldwide drug delivery systems market. Several advances in the field of medication delivery systems have been made. The inclusion of three-dimensional printing is the most significant of these (3D-printing).

Dental Consumables Market- Dental consumables are used to treat dental illnesses such as tooth restoration, gingival tissue difficulties, dental impairments, dental caries, and periodontal diseases. The growing number of dental disorders around the world is driving the growth of the dental consumables industry. One of the primary drivers of the global dental consumables market is the growing emphasis on physical appearance. Asia Pacific's worldwide dental consumables market share is expected to expand significantly.

About Fact.MR

Market research and consulting agency with a difference! That's why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range from automatic & industry 4.0 to chemical & materialsand retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Reach out to uswith your goals, and we'll be an able research partner.

Contact:

Mahendra SinghUS Sales Office:11140 Rockville PikeSuite 400Rockville, MD 20852United StatesTel: +1 (628) 251-1583E: sales@factmr.com

Logo: https://mma.prnewswire.com/media/713666/FactMR_Logo.jpg

View post:
Bioactive Material Sales to Triple Over Current Valuation, Reaching US$ 6.2 Bn by 2031 - Markets Insider

Last Price$ Last TradeChange$ Change Percent %Open$ Prev Close$ High$ low$ 52 Week High$ 52 Week Low$ Market CapPE RatioVolumeExchange

ORGO - Market Data & News

Today, Organogenesis Holdings Inc - Class A Incs (NASDAQ: ORGO) stock fell $0.35, accounting for a 2.36% decrease. Organogenesis opened at $14.66 before trading between $15.36 and $14.39 throughout Wednesdays session. The activity saw Organogenesiss market cap fall to $1,854,036,126 on 575,844 shares -below their 30-day average of 721,957.

Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis's comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs.

Visit Organogenesis Holdings Inc - Class A's profile for more information.

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Organogenesis Holdings Inc - Class A and to follow the company's latest updates, you can visit the company's profile page here: Organogenesis Holdings Inc - Class A's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE:The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Continue reading here:
Organogenesis (ORGO) falls 2.36% in Light Trading on August 4 - Equities.com

Last Price$ Last TradeChange$ Change Percent %Open$ Prev Close$ High$ low$ 52 Week High$ 52 Week Low$ Market CapPE RatioVolumeExchange

PSTI - Market Data & News

Pluristem Therapeutics Inc (NASDAQ: PSTI), a Building No 5, Haifa, company, fell to close at $3.15 Wednesday after losing $0.12 (3.67%) on volume of 257,328 shares. The stock ranged from a high of $3.28 to a low of $3.15 while Pluristems market cap now stands at $99,981,769.

Pluristem Therapeutics Inc. is a leading regenerative medicine company developing novel placenta-based cell therapy product candidates. The Company has reported robust clinical trial data in multiple indications for its patented PLX cell product candidates and is currently conducting late-stage clinical trials in several indications. PLX cell product candidates are believed to release a range of therapeutic proteins in response to inflammation, muscle trauma, hematological disorders and radiation damage. The cells are grown using the Company's proprietary three-dimensional expansion technology and can be administered to patients off- the-shelf, without tissue matching. Pluristem has a strong intellectual property position; a

Visit Pluristem Therapeutics Incs profile for more information.

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Pluristem Therapeutics Inc and to follow the companys latest updates, you can visit the companys profile page here: Pluristem Therapeutics Incs Profile. For more news on the financial markets be sure to visit Equities News. Also, dont forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE:The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Go here to read the rest:
Pluristem (PSTI) falls 3.67% in Active Trading on August 4 - Equities.com

The investment in bolstering defences in virtual space also remains a top priority, as the pharmaceutical industry is extremely susceptible to cyber-attacks due to the involvement of sensitive and valuable data.

Several pharmaceutical companies and research institutes including Hammersmith Medicines Research in the UK, the University of California, San Francisco (UCSF), and US-based clinical services company eResearch Technology (ERT) remained targets for cyberattacks due to their involvement in the development of COVID-19 vaccines.

GlobalData conducted to survey to assess to extent to which emerging technologies such as cybersecurity will help a company survive through the Covid-19 pandemic.

Analysis of the results found that 54% of the respondents opined that cybersecurity would play a significant role in helping companies to pull through the crisis created by the pandemic.

Cybersecuritys Role During COVID-19 Crisis

Another 33% of the surveyed companies expect cybersecurity to play a minor role during the COVID-19 crisis.

Further, 10% of the companies stated that cybersecurity will play no role during the pandemic, while 3% of the respondents were unaware of the impact of cybersecurity.

The analysis is based on responses received in GlobalData, Emerging Technologies Survey 2020 fielded between 29 May and 09 July 2020.

Go here to see the original:
Regenerative medicine: moving next-gen treatments from lab to clinic - Pharmaceutical Technology

New York, June 04, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Regenerative Medicine Market - Global Outlook and Forecast 2021-2026" - https://www.reportlinker.com/p06079941/?utm_source=GNW

Increased R&D investments by pharmaceutical companies will drive the demand for regenerative medicines. Europe plays a significant role in supporting the development and authorization of these products for several genetic and rare disorders. Increased funding via several venture capitalists and governments, and private institutions contribute significantly to the global regenerative medicine market growth. The increased prevalence of diseases such as cardiovascular diseases and diabetes can drive cell and gene therapy and tissue-engineered products. With the rise in thermal burns, occupational burn accidents, and chronic wounds, regenerative medicine products will experience steady growth. Novartis and Gilead Sciences are the key companies offering various therapies to treat cancer, genetic, and rare disorders.

The following factors are likely to contribute to the growth of the regenerative medicine market during the forecast period: Increase in the Patient Pool with Acute, Chronic, and Genetic Disorders Strong Pipeline Portfolio of Regenerative Medicine Companies Implementation of Advanced tissue-engineering Therapies Technology Faster Regulatory approvals

The report considers the present scenario of the regenerative medicine market and its market dynamics for 2019?2026. It covers a detailed overview of several market growth enablers, restraints, and trends. The study covers both the demand and supply sides of the market. It also profiles and analyzes leading companies and several other prominent companies operating in the market.

REGENERATIVE MEDICINE MARKET SEGMENTATION The regenerative medicine market research report includes a detailed segmentation by application, products, end-users, geography. Oncology constitutes the largest portion of the global regenerative medicine market share. The development of curative therapies by CAR-T and cell and gene therapies is widely popularized in the oncology therapeutic area. The increasing global prevalence rates and the increasing rates of different types of life-threatening cancers are the most important key factors that drive the oncology segment.

Consistent innovations in gene therapies due to the increased number of clinical trials and pipeline products are driving the growth prospects. Hence, the increased inflow of funding for the development of gene therapy is one of the driving factors for the sector growth Cell therapy is the major revenue contributor. The increasing prevalence of diabetes and foot ulcers is the primary factor contributing to the growth of tissue-engineered products. The tissue-engineered product segment to grow at a CAGR of 8% by 2026.

Hospitals are likely to remain a dominant revenue contributor to the global regenerative medicine market. Around 50% of therapeutic surgeries performed in the US annually, including cardiovascular and musculoskeletal, occur in hospitals. Cancer care centers are likely to witness an incremental growth of approx. USD 10 billion by 2026. As cancer is the second leading cause of death across the globe, which is responsible for approx. 10 million deaths annually, the scope of cancer centers is growing. Key vendors are focusing more on cancer care centers than hospitals to promote their products. As the cancer centers are being covered under reimbursement schemes, the growth of these facilities is likely to increase during the forecast period.

Segmentation by Application Oncology Genetic Disorders Dermatology Musculoskeletal Others

Segmentation by Product Gene Therapies Cell Therapies Tissue-Engineered Therapies

Segmentation by End-Users Hospitals Cancer Care Centers Wound Care Centers ASCs Others

INSIGHTS BY GEOGRAPHY In North America, the acceptance of regenerative medicine is relatively higher than in other developed countries. North America to accounts for the largest market share of the global regenerative medicine market. The growth can be primarily attributed to the increasing population with different types of cancers such as non-Hodgkin lymphoma, Hodgkin lymphoma, melanoma of the skin, and leukaemia in the North American region. Furthermore, North America consists of the highest number of regenerative medicine companies, which is adding to the market growth in the region. Europe has highly developed manufacturing facilities, which is driving the market growth in the European region. Most vendors in Europe depend on external sources for expansion and R&D activities.

Segmentation by Geography North America o US o Canada Europe o Germany o France o UK o Italy o Spain APAC o Japan o China o Australia o South Korea o India Latin America o Brazil o Mexico Middle East & Africa o Turkey o Saudi Arabia o South Africa o UAE

COMPETITIVE LANDSCAPE Amgen, Bristol Myers Squibb, Dendreon, F. Hoffmann-La Roche, Gilead Sciences, Novartis, Osiris, Organogenesis, and Vericel are the key vendors in the global regenerative medicine market. Global key players dominate the market shares due to wide distribution networks, innovative product launches, and broad product offerings. Companies are focusing on product innovations and strengthening their distribution channel to expand market presence globally. The market has developed innovative therapies in the field. For instance, Bristol Myers Squibb received approval from the US FDA for its product Lisocel - to treat relapsed/refractory diffuse large-B cell lymphoma (DLBCL) in February 2021. Small players are collaborating with prominent players to gain a competitive advantage in the market.

Key Vendors Novartis Gilead Sciences Amgen Organogenesis Bristol Myers Squibb Vericle Osiris Therapeutics

Other Prominent Vendors Anges Orchard Therapeutics Orthofix Integra Life Science MiMedx bluebird bio Mesoblast Avita Medical Takeda Pharmaceuticals Medipost TissueTech Misonix J-TEC Stempeutics CO.DON GC Pharma Orthocell Tego Science Nipro S-BIOMEDIC APAC Biotech Bio Solution Chiesi Farmaceutici Collplant Corestem Human Stem Cell Institute JCR Pharmaceuticals JW CreaGene Nuvasive Sibiono GeneTech Shanghai Sunway Biotech Terumo

KEY QUESTIONS ANSWERED: 1. How big is the regenerative medicine market? 2. What are the critical applications of regenerative medicine products? 3. Who are the key players in the regenerative medicine market? 4. Which segment accounted for the largest regenerative medicine market share? 5. Which region holds the largest share in the global regenerative medicine market? 6. How has the COVID-19 pandemic affected the regenerative medicine industry?Read the full report: https://www.reportlinker.com/p06079941/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

See the rest here:
The regenerative medicine market size to grow at a CAGR of around 30% during the period - GlobeNewswire

The range of products are designed to help veterinarians address common - and sometimes debilitating - injuries in horses

PARSIPPANY, N.J., June 1, 2021 /PRNewswire/ -- Zoetis Inc., the world's leading animal health company, announced that it will expand its portfolio of equine horse care products, with the addition of Pro-Stride APS, Restigen PRP and CenTrate BMA, a range of devices designed to help address injuries common in horses that may cause lameness.

Equine lameness as a result of musculoskeletal pain, particularly osteoarthritis, is one of the top reasons for veterinary evaluation1 and can have significant physical, economic and quality-of-life impact to both horse and owner. Horse joint health care is an increasingly important segment in equine medicine2.

These stall-side devices offer the opportunity to harness a horse's own natural healing mechanisms to manage joint and soft tissue ailments. A major benefit of using these devices is the ability for easy stall-side processing of the horses' blood or bone marrow, allowing for immediate use within 15 20 minutes of centrifugation; eliminating the need for incubation or off-site preparation.

"A healthy horse means more time in the saddle. Zoetis is committed to delivering solutions you can count on through continuous innovation across the continuum of care," said Jeannie Jeffery, Vice President, U.S. Equine for Zoetis. "The addition of Pro-Stride APS, Restigen PRP, and CenTrate BMA expands our ability to provide equine veterinarians additional options to advance joint and soft tissue care and is an exciting demonstration of our commitment to horse health and wellbeing."

Pro-Stride APS, Restigen PRP and CenTrate BMA complement the ever-expanding Zoetis family of horse care products. Zoetis will exclusively sell these products to veterinarians through key distributor partners. For more information please call Zoetis Customer Service at 1-888-Zoetis1 (1-888-963-8471).

Story continues

About ZoetisAs the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After nearly 70 years innovating ways to predict, prevent, detect, and treat animal illness, Zoetis continues to stand by those raising and caring for animals worldwide - from livestock farmers to veterinarians and pet owners. The company's leading portfolio and pipeline of medicines, vaccines, diagnostics, and technologies make a difference in over 100 countries. In 2020, Zoetis generated revenue of $6.7 billion with ~11,300 employees. For more, visit http://www.zoetis.com.

1.

USDA. 2000. Lameness and Laminitis in U.S. Horses. USDA:APHIS:VS, CEAH, National Animal Health Monitoring System. Fort Collins, CO. #N318.0400.

2.

Velloso Alvarez, A, et al., A Survey of Clinical Usage of Non-steroidal Intra-Articular Therapeutics by Equine Practitioners. Front Vet Sci, 2020

All trademarks are the property of Zoetis Services LLC or a related company or a licensor unless otherwise noted. 2021 Zoetis Services LLC. All rights reserved. GEQ-00751

Media Contacts:Colleen CosgroveZoetis 862-217-3250 Colleen.cosgrove@zoetis.com

Lauren Klingler Tynan609-213-3414lauren.klinglertynan@mslgroup.com

Cision

View original content:http://www.prnewswire.com/news-releases/zoetis-adds-devices-for-use-in-regenerative-medicine-therapies-to-its-growing-equine-portfolio-301303068.html

SOURCE Zoetis Inc.

View post:
Zoetis Adds Devices for Use in Regenerative Medicine Therapies to its Growing Equine Portfolio - Yahoo Finance